Imunon, Inc. (NASDAQ:IMNN – Get Free Report) dropped 7.2% on Thursday . The stock traded as low as $0.89 and last traded at $0.91. Approximately 201,898 shares were traded during trading, a decline of 38% from the average daily volume of 325,799 shares. The stock had previously closed at $0.98.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on IMNN. D. Boral Capital reaffirmed a “buy” rating and set a $29.00 price target on shares of Imunon in a report on Thursday, December 19th. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Imunon in a report on Thursday, December 19th.
Read Our Latest Stock Report on Imunon
Imunon Trading Down 1.1 %
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Stories
- Five stocks we like better than Imunon
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Stock Market Upgrades: What Are They?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
